Theravance to divide into two companies

Theravance will on 15 May 2014 divide into two companies. Late stage partnered respiratory assets will be held by Theravance Inc., a royalty management company and will develop the partnership with GSK involving Relvar/Breo Ellipta and Anoro Ellipta. The partnership also covers Vilanterol monotherapy, an early stage muscarinic antagonist and GSK 961081. Theravance Biopharma will focus on research and development and commercialisation of small molecule candidates in bacterial infections, CNS/Pain, respiratory diseases and GI Motility Dysfunction. Theravance Biopharma is currently developing TD 4208 ( a muscarinic antagonist), TD 9855 ( a norepinephrine + serotonin reuptake inhibitor for Fibromyalgia), TD 8954 ( a selective 5-HT4 receptor agonist for Enteral Feeding Intolerance, velusetrag (a 5-HT4 selective agonist for Gastroparesis and anti-infective Vibativ (telavancin).